Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened ...
Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission - - Strengthened ...
PIPELINE AND CORPORATE HIGHLIGHTS SENTI-202 for AML ... and two achieved complete remission ("CR"), confirmed by bone marrow biopsy, which includes blast reduction and recovery of blood cells ...
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage ...
Senti Bio (SNTI)sciences announced an expansion of its senior leadership team with the addition of Jay Cross as CFO and Faraz Siddiqui as Senior Vice President of Technical Operations. Mr. Cross ...
SOUTH SAN FRANCISCO - Senti Biosciences, Inc. (NASDAQ:SNTI), a biotech firm specializing in gene therapy with a market capitalization of $84.17 million, announced the appointment of Feng Hsiung to ...
Senti Biosciences, Inc. (NASDAQ:SNTI), a biotech company with a market capitalization of $16.46 million and currently trading at $3.47, has announced the appointment of new board member Feng ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback